FIGURES
Figure 4.1. Schematic of the Domain Structure of the Hepatitis C Virus

TABLES
Table 2.1. Global Distribution of HIV Infection in 2005
Table 2.2. Incidence of Hepatitis A Infection in the United States
Table 2.3. Incidence of Hepatitis B Infection in the United States
Table 2.4. Incidence of Hepatitis C Infection in the United States
Table 3.1. Marketed HIV Reverse Transcriptase Inhibitors
Table 3.2. Marketed HIV Protease Inhibitors
Table 3.3. Leading Vaccine Products for the Treatment of Hepatitis Infections
Table 3.4. Therapeutic Agents for the Treatment of Hepatitis Infections
Table 3.5. Viral Replication Inhibitors for the Treatment of Herpes Simplex Infections
Table 3.6. Viral Replication Inhibitors for the Treatment of CMV Retinitis
Table 4.1. Agents in Clinical Development for the Treatment of HIV Infection
Table 4.2. HIV Vaccines That Are Currently in Clinical Development
Table 4.3. Novel Agents in Development for the Treatment of Hepatitis C Infection
Table 4.4. Novel Agents in Development for the Treatment of Hepatitis B Infection
Table 4.5. Novel Agents in Clinical Development for the Treatment of Herpes Infections
Table 4.6. Novel Agents in Development for the Treatment of Papilloma Infection
Table 4.7. Potential Market for HPV Vaccines
Table 4.8. Novel Influenza Vaccines in Development
Table 5.1. Antiviral Products Marketed by Abbott Laboratories
Table 5.2. Antiviral Agents in Clinical Development by Achillion
Table 5.3. Antiviral Products Marketed by Boehringer Ingelheim
Table 5.4. Boehringer Ingelheim’s Pipeline of Antiviral Agents
Table 5.5. Biota’s Antiviral Development Pipeline
Table 5.6. Bristol-Myers Squibb’s Antiviral Products
Table 5.7. Bristol-Myers Squibb’s Antiviral Pipeline
Table 5.8. Chiron’s Leading Antiviral Vaccines
Table 5.9. Chiron’s Pipeline of Antiviral Vaccines
Table 5.10. Enzo’s Antiviral Pipeline
Table 5.11. Gilead’s Portfolio of Antiviral Drugs
Table 5.12. Gilead’s Antiviral Pipeline
Table 5.13. GlaxoSmithKline’s Portfolio of Antiviral Products
Table 5.14. GlaxoSmithKline’s Antiviral Pipeline
Table 5.15. Roche’s Portfolio of Antiviral Drugs
Table 5.16. Roche’s Antiviral Pipeline
Table 5.17. Idenix’ Antiviral Pipeline
Table 5.18. Japan Tobacco’s Antiviral Pipeline
Table 5.19. Johnson & Johnson’s Antiviral Pipeline
Table 5.20. Medivir’s Antiviral Pipeline
Table 5.21. Merck’s Portfolio of Antiviral Products
Table 5.22. Merck’s Antiviral Pipeline
Table 5.23. Novartis’ Antiviral Pipeline
Table 5.24. Pfizer’s Portfolio of Antiviral Drugs
Table 5.25. Pfizer’s Antiviral Pipeline
Table 5.26. sanofi pasteur’s Portfolio of Viral Vaccines
Table 5.27. sanofi pasteur’s Antiviral Pipeline
Table 5.28. Schering-Plough’s Portfolio of Antiviral Drugs
Table 5.29. Schering-Plough’s Antiviral Pipeline
Table 5.30. Valeant’s Portfolio of Antiviral Drugs
Table 5.31. Valeant’s Antiviral PipelineTable 5.32. Vertex’ Antiviral Pipeline
Table 5.33. ViroPharma’s Antiviral Pipeline